What Fibrovein 1% Treats: Main Uses and Benefits

Fibrovein 1% is applied across domains where additional symptomatic support is needed to address the visible manifestations of specific vein conditions in the lower extremities. The medication is commonly used across conditions presenting with acute episodes and is relevant in conditions characterized by periods of heightened symptoms. Its primary function is applied in addressing symptoms that interfere with daily functioning and supports patient comfort by managing the acute or recurrent symptom burden associated with venous disease.

Fibrovein 1% may be part of symptomatic management for conditions involving episodic or fluctuating manifestations, including uncomplicated primary varicose veins, recurrent or residual varicose veins following surgery, reticular veins, venules, and spider veins of the lower extremities.

“This application supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.”

Easing Symptoms Related to Small-to-Medium Veins

This concentration is commonly used to help with symptoms linked to small varicose veins and larger venules. It is applied in addressing symptoms related to physical discomfort, such as the aching, heaviness, or burning sensation, often associated with these visible vein clusters. The application may assist with managing symptom intensity and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Physical Discomfort

Fibrovein 1% is also relevant in clinical settings for addressing recurrent or residual vein manifestations following previous procedures, playing a role in managing symptoms that create noticeable functional strain.

Regulatory References

1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Who Can and Cannot Use Fibrovein 1%

Eligibility for Fibrovein 1% (Sodium Tetradecyl Sulfate) is strictly defined by regulatory documents, restricting its use primarily to the adult population and excluding individuals with specific high-risk conditions, most notably those related to blood clotting.

Populations for Whom Use is Contraindicated

Use of this medicine is absolutely prohibited (contraindicated) in patients with the following conditions, as stated in official labeling:

• Active Thromboembolic Events: Recent acute superficial thrombophlebitis, deep vein thrombosis (DVT), or pulmonary embolism (PE).
• High Thrombotic Risk: Congenital predisposition to blood clots, hormonal contraception/HRT use, significant obesity, smoking, or extended immobility.
• Vascular Issues: Significant valvular incompetence of the deep veins, occlusive arterial disease, or varicosities caused by pelvic/abdominal tumors.
• Uncontrolled Disease: Uncontrolled systemic diseases, such as uncontrolled diabetes mellitus, sepsis, or evolving cancer.
• Hypersensitivity: Known allergy to Sodium Tetradecyl Sulfate or any excipient.
• Immobility: Patients who are bedridden or otherwise unable to walk.

Restricted and Non-Recommended Groups

The medicine is only intended for use in adults; use in children and adolescents is not recommended as safety and effectiveness have not been established. Use during pregnancy is not recommended as safety is unestablished. Caution should be exercised when used in nursing mothers or patients with a history of neurological events like migraines or stroke.

Fibrovein 1% Interactions with other medicines and products

This section describes documented interaction patterns for Fibrovein 1% (Sodium Tetradecyl Sulfate) based strictly on official government regulatory information. As a locally-administered sclerosing agent, its interaction profile is primarily constrained by procedural requirements and pharmacodynamic risks related to blood function.

---

Procedural and Local Interaction Constraints

The official regulatory documentation identifies a key constraint regarding preparation: Fibrovein 1% solution is formally incompatible with heparin and must not be mixed with it in the same syringe or during administration. In general, the product must not be mixed with any other medicinal products in the absence of documented compatibility studies. This restriction is classified as a physical/chemical incompatibility.

---

Pharmacodynamic Interaction Cautions

A pharmacodynamic caution exists for co-administered medicines that influence blood function. Substances such as anti-platelet agents and fibrinolytic agents may increase the local risks associated with the sclerotherapy procedure. Furthermore, official prescribing information notes that treatment of patients taking antiovulatory agents (hormonal contraceptives) or Hormone Replacement Therapy requires evaluation, as there is a documented potential association with increased thromboembolic risk.

---

Absence of Systemic Drug Interactions

Regulatory data do not document any significant systemic interaction patterns. Specifically, no interactions involving metabolic enzymes (Cytochrome P450) or drug transport proteins are cited. Similarly, no specific interactions with food, alcohol, or herbal supplements are documented in official regulatory labeling.

The mechanism of action for Fibrovein 1% (Sodium Tetradecyl Sulfate) is a chemical-induced biological cascade initiated by a direct interaction, leading sequentially to cellular damage, coagulation, and long-term tissue remodeling.

---

Molecular Action: Endothelial Cell Lysis

The drug’s core effect is rooted in its nature as an anionic surfactant. When injected, the molecule exerts a detergent action, physically disrupting the lipid and protein structure of the vascular endothelium (the inner cell lining of the vessel). This non-specific, cytotoxic interaction causes immediate and controlled cellular injury (lysis), which is the required initiation step for the subsequent coagulation cascade.

---

Pathway Effect: Thrombosis and Vessel Occlusion

The destruction of the endothelial barrier rapidly exposes the underlying pro-clotting tissue to the blood, triggering the coagulation cascade. This swift activation of the hemostatic pathways leads to platelet aggregation and the formation of a dense, localized thrombus (blood clot). The resulting physiological change is the complete and immediate occlusion of the treated vessel segment, blocking blood flow.

---

Long-Term Remodeling: Sclerosis

Following the acute clotting event, the mechanism shifts into a tissue remodeling phase. Over time, the temporary thrombus is biologically organized and replaced by fibrous connective tissue, a process known as sclerosis. This final step involves the organization of the thrombus into fibrous tissue (sclerosis), resulting in the anatomical closure of the treated vessel.

Fibrovein 1% is officially administered exclusively via intravenous injection and requires delivery by a healthcare professional with specialized expertise in the procedure of sclerotherapy. This method of use is strictly limited to the minimal effective volume necessary to treat the targeted vein segment, and a test dose may be administered prior to the main treatment session.

Official dosing guidelines establish a precise volume range for a single injection site, typically between 0.1 mL and 1.0 mL of the 1% solution. A strict limit is placed on the maximum total volume per session, which must not exceed 10 mL of the liquid solution. The product may be used in its liquid form or prepared immediately before injection as a foam (sclerosant/air mixture), which is often administered under ultrasound guidance.

Following the completion of the procedure, the administration protocol requires the immediate application of continuous compression to the treated area. This compression is considered an essential component of the overall administration process and is typically maintained for several weeks. Standard prescribing information provides no specific dose recommendations for older adults, and use is not established in the pediatric population.

Evidence for Use in Primary Varicose Veins

Research into the use of this medicine for small to medium primary varicose veins includes randomized controlled trials (RCTs), systematic reviews, and meta-analyses. These studies monitored adult populations and examined outcomes related to physical discomfort by measuring the physical closure or obliteration of the treated vein, typically confirmed using ultrasound. Reports monitored patterns in measured outcomes and patient-reported outcomes describing perceived discomfort. Findings exhibited heterogeneity across studies. Long-term effects regarding the maintenance of vein closure are not fully established beyond the one-year mark, as follow-up durations were limited in many primary studies.

---

Evidence for Recurrent and Residual Veins

Research for veins that have persisted or returned after a prior treatment has relied largely on observational studies and retrospective case series. This research was evaluated in adult populations with a history of previous vein treatment. Studies explored the rate at which residual veins were observed and monitored outcomes reflecting daily functioning. Since the evidence is primarily derived from observational settings, the certainty remains low compared to larger controlled trials, and sample sizes were modest in many reports.

---

Evidence for Telangiectasias and Reticular Veins

For the smallest vessels (spider veins and venules), research has primarily focused on visual resolution or cosmetic improvement using standardized grading scales, alongside patient scores related to localized discomfort. Research included randomized controlled trials, which often compared this treatment against other similar sclerosing agents. Follow-up durations were limited, and the long-term effects on the potential for these smaller vessels to reappear are not fully established.

---

Summary of Evidence Gaps

The research base consistently notes limitations: follow-up durations were limited in many core studies, meaning the long-term durability of the effect is not fully established. Additionally, evidence quality varies across studies due to methodological differences. Data for specific patient groups, such as pediatric populations or pregnant individuals, appears to be limited. Comparative evidence against non-active controls is also less frequent than comparisons between different active treatments.

Key Studies & References Summary of Product Characteristics (SPC) - Fibrovein 1% (Health Products Regulatory Authority, HPRA)

Common questions about Fibrovein 1% (FAQ)

---

Q: Are there different concentrations of Fibrovein, and what does the 1% mean?

Official product information notes that Fibrovein is generally available in different strengths, such as 0.5%, 1%, and 3%. The 1% strength indicates the concentration of the active ingredient, Sodium Tetradecyl Sulfate, in the solution. This specific concentration is often used for treating small varicose veins and larger venules.

---

Q: Is Fibrovein 1% the same as other medicines used for varicose veins?

Fibrovein 1% belongs to a class of medicines known as sclerosing agents, which are used to intentionally close specific blood vessels. While other sclerosing agents exist, they may contain different active ingredients. Fibrovein 1% specifically contains Sodium Tetradecyl Sulfate.

---

Q: How long does the effect of Fibrovein 1% usually last?

The mechanism of action described in official documents is intended to cause the treated vein to become permanently closed through sclerosis. However, official research evidence often has limited follow-up periods, indicating that the long-term durability of the vein closure has not been fully established beyond the one-year mark.

---

Q: Do studies suggest Fibrovein 1% is a permanent treatment?

Official documents describe the drug's mechanism of action as leading to the permanent closure and obliteration of the treated vein. While the resulting tissue change (sclerosis) is permanent, regulatory research summaries note that evidence on the long-term durability of the effect has not been fully established in studies with limited follow-up.

---

Q: Is it normal to feel pain after a Fibrovein 1% procedure?

Yes, official documents list pain or burning at the injection site as a common side effect, which means it can affect up to 1 in 10 patients. The pain or burning at the injection site is listed as a common reaction.

---

Q: Can people with a history of blood clots use Fibrovein 1%?

The medicine is contraindicated in patients with active blood clotting events, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). Caution is also advised for patients with a history of certain neurological events, such as a transient ischemic attack (TIA) or stroke.

---

Q: Is Fibrovein 1% suitable for pregnant women?

The safety of using Fibrovein during pregnancy has not been established in studies. Official prescribing information notes that the use of this medicine during pregnancy is generally not recommended.

---

Q: Does Fibrovein 1% interact with blood thinning medication?

Official documentation advises caution for patients taking medicines for the treatment of blood clots, often called 'blood thinners,' such as anti-platelet or fibrinolytic agents. These substances may increase the local procedural risks associated with the sclerotherapy treatment.

---

Q: What type of doctor typically administers Fibrovein 1%?

Fibrovein should only be administered by a medical practitioner with specific qualifications and experience in injection sclerotherapy. The procedure may also be performed by appropriately qualified medical personnel under the supervision of such a specialized physician.

---

Q: How quickly do people usually see results from Fibrovein 1%?

Information for the user states that after the procedure, the treated vein turns into scar tissue, and the vein should fade. This process typically occurs over a period of a few weeks.

---

Q: Can Fibrovein 1% affect the color or appearance of the skin?

Skin discoloration, known as hyperpigmentation, is listed as an uncommon side effect. This condition is related to the appearance of the skin and is noted in official documentation.

---

Q: What is the typical recovery period mentioned in official documents for Fibrovein 1%?

Official administration instructions describe the continuous application of compression to the treated area as a necessary part of the procedure for a period of several weeks. The specific duration of recovery may depend on the size of the veins treated.

---

Q: What happens if some of the Fibrovein 1% goes into surrounding tissues?

Accidental injection outside the vein (extravasation) carries a risk of local tissue death, known as necrosis, and ulceration of the skin and underlying tissue, which is listed as a rare side effect. Official warnings note the risk of severe complications if the product is accidentally injected into an artery.

---

Q: Can children or adolescents use Fibrovein 1%?

Use in children and adolescents is not recommended because the safety and effectiveness have not been established in this patient group. The medicine is intended for use only in adults.

---

Q: Does Fibrovein 1% have any known effects on kidney or liver function?

Official warnings note that the product contains an excipient (benzyl alcohol) that may accumulate in the body and potentially cause side effects in patients with existing severe liver or kidney disease. Specific direct effects of the active ingredient are not listed.

---

Q: Are there any special preparations needed before a Fibrovein 1% treatment?

Official guidelines indicate that patients should be evaluated for any issues related to the closing of valves in their deep veins prior to treatment. Additionally, a small test dose may be administered before the main session to check for any potential hypersensitivity.

---

Q: Is Fibrovein 1% a brand name, and what is the generic name?

Fibrovein is the brand name of the medicine. The generic name, which refers to the active ingredient, is Sodium Tetradecyl Sulfate (STS).

---

Q: Do studies show a difference in results for different vein sizes when using Fibrovein 1%?

Regulatory guidelines state that the strength of Fibrovein selected depends on the size of the veins to be treated. The 1% concentration is specifically recommended for small varicose veins and larger venules, suggesting that the concentration is optimized for certain vein sizes to achieve the intended results.

---

Q: How is the safety profile of Fibrovein 1% described in official regulatory documents?

The safety profile is described by classifying adverse reactions based on their frequency of occurrence, such such as Common, Uncommon, Rare, and Very Rare. The most serious risks listed in regulatory documents are major blood clots (thromboembolic events) and severe allergic reactions (anaphylactic shock).

---

Q: What is the difference between Fibrovein 1% and a foam-based sclerotherapy?

Fibrovein 1% is supplied as a liquid solution. It can be administered directly as a liquid or prepared immediately before injection as a foam (a mixture of the solution and air). The foam preparation is often used for treating larger veins.

---

Q: Is it true that patients need to wear compression stockings after Fibrovein 1%?

Official administration documents describe the immediate and continuous application of compression to the treated area as a necessary part of the procedure following the injection. This is a vital component of the treatment process, which often involves the use of compression stockings or bandages.

---

Q: Are there any specific lifestyle changes suggested after receiving Fibrovein 1%?

The use of continuous compression for several weeks is the primary procedural requirement. Some post-treatment guidelines also suggest avoiding significant sun exposure for a period after the treatment to potentially help reduce the incidence of skin pigmentation.

---

Q: Can Fibrovein 1% be used more than once in the same area?

Due to the limited volume of medicine authorized per single treatment session, repeated sessions of sclerotherapy may be necessary to fully treat the affected area.

---

Q: Is the procedure with Fibrovein 1% painful?

Official documents list pain or burning at the injection site as a common side effect (up to 1 in 10 patients). Pain or burning at the injection site is listed as a common reaction.

How to Store and Dispose of Fibrovein 1%

Fibrovein 1% solution must be stored under specific environmental and safety conditions defined in regulatory documents to ensure its integrity.

Storage Requirements

Condition	Requirement
Temperature	Do not store above 25 C and must not be frozen.
Protection	Keep the ampoule or vial in the original outer carton to protect the solution from light.
Child Safety	Store out of the sight and reach of children.
Shelf-life	The unopened product has a labeled shelf-life of three years.

Handling and Disposal

Fibrovein 1% is a single-use product, meaning any contents remaining in the container after the solution is opened must be discarded immediately. For disposal, the medicine must not be placed into household waste or wastewater. Expired or unused Fibrovein 1% and related waste materials must be disposed of according to local regulatory requirements.